Kyntra Bio, Inc. (KYNB): who owns it and who trades it
As of Nov 16, 2026, KYNB insiders reported 2 purchases worth $44.4K in the last 12 months. The largest buyer was Thane Wettig (CEO), with $44.4K. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Kyntra Bio
From the latest filingsOverall: more buying than selling. Insiders and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Insider trades
In the last 12 months, KYNB insiders reported $44.4K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| May 14, 2026 | Thane Wettig | CEO | Purchase | 2,800 | $7.09 | $19.9K | Form 4 |
| Nov 17, 2025 | Thane Wettig | CEO | Purchase | 2,700 | $9.10 | $24.6K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Thane Wettig | CEO, Director | $44.4K | – | May 14, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
KYNB short interest
Low short interest. 2.4% of KYNB shares are sold short: about 1 share in 42. Over the last 12 reports the number of shares short went down 16%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 95,811 KYNB shares were sold short, 2.4% of the shares outstanding, up 0.9% from the report before. At the average daily volume of 20,459 shares, buying them all back would take about 4.7 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 95,811 | 2.37% | +1% | 20,459 | 4.7 |
| Oct 15, 2026 | 94,984 | 2.35% | -5% | 26,762 | 3.5 |
| Sep 30, 2026 | 100,040 | 2.47% | -1% | 26,755 | 3.7 |
| Sep 15, 2026 | 100,711 | 2.49% | -5% | 23,678 | 4.2 |
| Aug 31, 2026 | 105,781 | 2.61% | +8% | 22,838 | 4.6 |
| Aug 14, 2026 | 98,197 | 2.43% | +1% | 6,925 | 14.2 |
| Jul 31, 2026 | 97,565 | 2.41% | -0% | 5,780 | 16.9 |
| Jul 15, 2026 | 97,707 | 2.41% | -11% | 16,256 | 6.0 |
| Jun 30, 2026 | 109,506 | 2.71% | -4% | 17,190 | 6.4 |
| Jun 15, 2026 | 114,616 | 2.83% | -2% | 50,514 | 2.3 |
| May 29, 2026 | 116,425 | 2.88% | +2% | 7,849 | 14.8 |
| May 15, 2026 | 113,844 | 2.81% | +0% | 8,640 | 13.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Kyntra Bio company events
Kyntra Bio filed 10 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership, listing). The latest was on Oct 6, 2026.
- Oct 6, 2026ListingKyntra Bio, Inc. received a determination letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC notifying the Company that it had not yet demonstrated compliance with Nasdaq Listing Rule 5450(b) as of the September 29, 2026 deadline and that, as a result, the Staff had… Filing
- Oct 1, 2026LeadershipThe Board of Directors of the Kyntra Bio, Inc. appointed Andrew E. Singer, MBA as a Class III director of the Company. Filing
- Aug 31, 2026AgreementKyntra Bio, Inc. entered into an amended and restated agreement with NQ Project Phoebus, L.P., amending the original Revenue Interest Financing Agreement, dated November 4, 2022. Filing
- Aug 13, 2026ResultsReleased financial results. Filing
- Jun 16, 2026VoteReported shareholder vote results. Filing
- Jun 9, 2026AnnouncementKyntra Bio, Inc. received $4.0 million from AstraZeneca Treasury Limited. Filing
- May 11, 2026ResultsReleased financial results. Filing
- Apr 9, 2026ListingKyntra Bio, Inc. received a letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market notifying us that the Company no longer complies with the Nasdaq Global Select Market continued listing requirement of $50 million in total assets and total revenue for the most recently… Filing
- Mar 16, 2026ResultsReleased financial results. Filing
- Jan 7, 2026AnnouncementThe Company issued a press release announcing its name change to Kyntra Bio. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Kyntra Bio financials
Famous investors that hold KYNB
2 of the 50 well-known investors we track reported holding KYNB in their latest 13F filing. The largest position is Jim Simons's, worth $235K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 35,281 | $235K | 0.0% | +30% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 24,144 | $161K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named KYNB in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Armistice Capital, LLC | 13G/A | 9.9% |
| Nov 16, 2026 | Armistice Capital, LLC | 13G/A | 9.9% |
Questions about Kyntra Bio, Inc. (KYNB) stock
Are KYNB insiders buying or selling?
In the last 12 months, KYNB insiders reported 2 open-market purchases worth $44.4K and no sales. The latest trade was on May 14, 2026. See every trade.
What is the short interest in KYNB?
As of Oct 30, 2026, 95,811 KYNB shares were sold short, 2.4% of the shares outstanding, up 0.9% from the report before. At the average daily volume of 20,459 shares, buying them all back would take about 4.7 trading days (days to cover). See the history.
Which famous investors hold KYNB?
2 of the 50 well-known investors we track reported KYNB in their latest 13F filing, including Jim Simons, Ken Griffin. The largest position is worth $235K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.